Author(s):
Magalhães, Mariana ; Domínguez-Martín, Eva María ; Jorge, Joana ; Gonçalves, Ana Cristina ; Massenzio, Francesca ; Spigarelli, Renato ; Ribeiro-Rodrigues, Teresa ; Catarino, Steve ; Girão, Henrique ; Monti, Barbara ; Spisni, Enzo ; Ferreira, Lino ; Oliveira, Paulo J. ; Efferth, Thomas ; Rijo, Patrícia ; Cabral, Célia Margarida dos Santos
Date: 2024
Persistent ID: https://hdl.handle.net/10316/116195
Origin: Estudo Geral - Universidade de Coimbra
Project/scholarship:
info:eu-repo/grantAgreement/other/04539//other;
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA/PT;
Subject(s): Abietane diterpenes; Antitumor activity; Glioblastoma; Plectranthus hadiensis schweinf.; Royleanone
Description
Glioblastoma (GB) is the most aggressive and prevalent glioma within the central nervous system. Despite considerable efforts, GB continues to exhibit a dismal 5-year survival rate (∼6%). This is largely attributed to unfavorable prognosis and lack of viable treatment options. Therefore, novel therapies centered around plant-derived compounds emerge as a compelling avenue to enhance patient survival and well-being. The South African species, Plectranthus hadiensis Schweinf. (P. hadiensis), a member of the Lamiaceae family, has a history of use in traditional medicine for treating a range of diseases, including respiratory, digestive, and liver disorders. This species exhibits diverse biological activities, such as anti-inflammatory and antitumoral properties, likely attributed to its rich composition of naturally occurring diterpenes, like the abietane diterpene, 7α-acetoxy-6β-hydroxyroyleanone (Roy). Roy has demonstrated promising antitumor effects in various cancer cell lines, making it a compelling candidate for further investigation into its mechanisms against GB.
